DGI:Lymeborreliose/Quellen - Revision history

imported>Brinkery at 13:37, 10 December 2020

2020-12-10T13:37:08Z

← Older revision		Revision as of 13:37, 10 December 2020
Line 1:		Line 1:
	== Quellen ==		==Quellen==

	* Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. ''Infect Dis Clin North Am''. 2015;29(2):269-280. doi:10.1016/j.idc.2015.02.004		*Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. ''Infect Dis Clin North Am''. 2015;29(2):269-280. doi:10.1016/j.idc.2015.02.004
	* Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. ''Arthritis Rheum''. 2006;54(10):3079-3086. doi:10.1002/art.22131		*Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. ''Arthritis Rheum''. 2006;54(10):3079-3086. doi:10.1002/art.22131
	* Grillon A, Scherlinger M, Boyer PH, et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. ''Semin Arthritis Rheum''. 2019;48(6):1105-1112. doi:10.1016/j.semarthrit.2018.09.007		*Grillon A, Scherlinger M, Boyer PH, et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. ''Semin Arthritis Rheum''. 2019;48(6):1105-1112. doi:10.1016/j.semarthrit.2018.09.007

			*<span class="ve-pasteProtect" style="box-sizing: inherit; font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}">Hofmann H, et al. ''S2k-Leitlinie Kutane Lyme Borreliose'', 2016</span>
			*<span class="ve-pasteProtect" style="box-sizing: inherit; font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}">Rauer S, Kastenbauer S. ''S3-Leitlinie Neuroborreliose'', 2018</span>
			*Kullberg BJ, et al., ''Lyme borreliosis: diagnosis and treatment.'' <span class="ve-pasteProtect" style="box-sizing: inherit; font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}">BMJ, 2020. 369:m1041. <span class="ve-pasteProtect" style="color: black" data-ve-attributes="{"style":"color: black"}">doi: 10.1136/bmj.m1041.</span> <span class="ve-pasteProtect" style="box-sizing: inherit;" data-ve-attributes="{"style":"box-sizing: inherit;"}"> </span></span>
			*<span class="ve-pasteProtect" style="box-sizing: inherit; font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}">Gaubitz M, et al., ''Empfehlungen der DGRh zur Therapie der Lyme-Borreliose, speziell des Erythema migrans sowie der Lyme-''</span>
			*NICE guideline 2018: ''Lyme disease''
			*Goodlet KJ, Fairman KA. ''Adverse Events Associated With Antibiotics and Intravenous Therapies for Post–Lyme Disease Syndrome in a Commercially Insured Sample.'' <span class="ve-pasteProtect" style="box-sizing: inherit; font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}">Clin Infect Dis, 2018; 67(10):1568-1574</span>

	~~Therapie:~~

	* <span class="ve-~~pasteProtect~~" style="box-sizing: inherit~~; font-family: Arial, sans-serif~~;" ~~data-ve-attributes~~="~~{"style":"~~box-sizing: inherit; ~~font-family: Arial, sans-serif;"}~~">~~Hofmann H, et al~~. ~~''S2k-Leitlinie Kutane Lyme Borreliose'', 2016~~</span>		* <span class="docsum-authors" style="box-sizing: inherit;"><span style="box-sizing: inherit;">Cook MJ.</span></span> [https://pubmed.ncbi.nlm.nih.gov/25565881/ <span style="box-sizing: inherit;">Lyme</span> <span style="box-sizing: inherit;">borreliosis</span>: a review of data on transmission time after tick attachment.] <span style="box-sizing: inherit;"> </span><span class="docsum-journal-citation" style="box-sizing: inherit;">Int J Gen Med. 2014 Dec 19;8:1-8</span>
	* <span ~~class="ve-pasteProtect"~~ style="box-sizing: inherit; ~~font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}~~">~~Rauer S, Kastenbauer S. ''S3-Leitlinie Neuroborreliose'', 2018~~</span>		* <span style="box-sizing: inherit; font-family: Arial, sans-serif;">Rahlenbeck S, Fingerle V „Ixodes ricinus Wie man sich vor Zecken schützt“ Deutsches Ärzteblatt Jg. 111 Heft 25 A 1142- A 1143</span>
	* Kullberg BJ, et al., ''Lyme borreliosis: diagnosis and treatment.'' <span ~~class="ve-pasteProtect"~~ style="box-sizing: inherit; ~~font-family: Arial, sans-serif;" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}~~">~~BMJ, 2020. 369~~:~~m1041~~. <span ~~class="ve-pasteProtect"~~ style="~~color: black" data~~-~~ve-attributes="{"style"~~:~~"color: black&quot~~;}">~~doi: 10.1136/bmj.m1041.~~</span> <span class="ve-~~pasteProtect~~" style="box-sizing: inherit;" ~~data-ve-attributes="{"style&quot~~;:~~"box~~-~~sizing: inherit;"}"> </span>~~</span>		* <span style="box-sizing: inherit; font-family: Arial, sans-serif;">AWMF Leitlinie der Deutschen Dermatologischen Gesellschaft AWMF-Register-Nr. 013/044 Klasse: S2k „Kutane Lyme Borreliose“ https://www.awmf.org/uploads/tx_szleitlinien/013-044l_S2k_Kutane_Lyme_Borreliose_2016-05.pdf (letzter Zugriff: )</span>
	* <span ~~class="ve-pasteProtect"~~ style="box-sizing: inherit; font-family: Arial, sans-serif;~~" data-ve-attributes="{"style":"box-sizing: inherit; font-family: Arial, sans-serif;"}~~">~~Gaubitz M~~, ~~et al~~.~~, ''Empfehlungen der DGRh zur Therapie der Lyme-Borreliose, speziell des Erythema migrans sowie der Lyme~~-''</span>		* Nau R, Christen HJ, Eiffert H „Lyme Disease – Current State of Knowledge“ Dtsch Ärztebl Int 2009; 106(5): 72-82 (Diskussion: https://www.aerzteblatt.de/pdf.asp?id=65524)<br />
	* ~~NICE guideline 2018: ''Lyme disease''~~
	* Goodlet KJ, Fairman KA. ''Adverse Events Associated With Antibiotics and Intravenous Therapies for Post–Lyme Disease Syndrome in a Commercially Insured Sample.'' <span ~~class="ve-pasteProtect"~~ style="box-sizing: inherit; font-family: Arial, sans-serif;" ~~data~~-ve-~~attributes="{"style"~~:~~"box~~-~~sizing: inherit; font~~-~~family~~: ~~Arial~~, ~~sans-serif;"}">Clin Infect Dis~~, ~~2018~~; 67(10):~~1568~~-~~1574<~~/~~span>~~

	<br />

imported>Brinkery at 13:04, 10 December 2020

2020-12-10T13:04:59Z

@@ Line 1: / Line 1: @@
-Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. ''Infect Dis Clin North Am''. 2015;29(2):269-280. doi:10.1016/j.idc.2015.02.004
+== Quellen ==
-Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. ''Arthritis Rheum''. 2006;54(10):3079-3086. doi:10.1002/art.22131
+* Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. ''Infect Dis Clin North Am''. 2015;29(2):269-280. doi:10.1016/j.idc.2015.02.004
-Grillon A, Scherlinger M, Boyer PH, et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. ''Semin Arthritis Rheum''. 2019;48(6):1105-1112. doi:10.1016/j.semarthrit.2018.09.007

imported>Brinkery: Die Seite wurde neu angelegt: „Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. ''Infect Dis Clin North Am''. 2015;29(2):269-280. doi:10.1016/j.idc.2015.02.004 Steere AC, A…“

2020-12-10T12:49:17Z

Die Seite wurde neu angelegt: „Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. ''Infect Dis Clin North Am''. 2015;29(2):269-280. doi:10.1016/j.idc.2015.02.004 Steere AC, A…“

New page

Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. ''Infect Dis Clin North Am''. 2015;29(2):269-280. doi:10.1016/j.idc.2015.02.004

Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. ''Arthritis Rheum''. 2006;54(10):3079-3086. doi:10.1002/art.22131

Grillon A, Scherlinger M, Boyer PH, et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. ''Semin Arthritis Rheum''. 2019;48(6):1105-1112. doi:10.1016/j.semarthrit.2018.09.007